{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00349104,0.002378311,0.002051574,0.00104555,0.000532765,0.001143409,0.00173049,0.001456052,0.004394241],"category_scores_gemma":[0.001221677,0.001134225,0.002014865,0.0006373993,0.001282831,0.001493744,0.0007104797,0.004390095,0.001071451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001518053,"about_ca_system_score_gemma":0.002447292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008640112,"about_ca_topic_score_gemma":0.002415756,"domain_scores_codex":[0.9990588,0.0004291232,0.00005114848,0.0001775427,0.0001077291,0.0001757218],"domain_scores_gemma":[0.9987588,0.0001485979,0.0002741838,0.0001519581,0.00006735188,0.0005990266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7101741,0.1596669,0.00332307,0.0007116578,0.001347211,0.0001775106,0.0002480684,0.004214264,0.05712755,0.0003345527,0.002563281,0.06011192],"study_design_scores_gemma":[0.5399032,0.4497955,0.003917787,0.00001717689,0.0003311874,0.0001388651,0.00002344779,0.0009776079,0.003290399,0.000190998,0.001381631,0.0000321085],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905084,0.0009690679,0.001212432,0.0003741493,0.0001285098,0.004281206,0.0008603957,0.0001280165,0.001537799],"genre_scores_gemma":[0.9800028,0.001245646,0.004988215,0.0008786224,0.0002240841,0.005907453,0.002699518,0.00004966136,0.004004062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004394241,"threshold_uncertainty_score":0.0184626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03309205630219511,"score_gpt":0.3685072594238245,"score_spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}